{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T10:16:50Z","timestamp":1780913810077,"version":"3.54.1"},"reference-count":114,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Clinical Research Special Fund of Wu Jieping Medical Foundation","award":["320.6750.2023-5-109"],"award-info":[{"award-number":["320.6750.2023-5-109"]}]},{"DOI":"10.13039\/501100011790","name":"Xiangya Hospital, Central South University","doi-asserted-by":"publisher","award":["2022LNJJ10"],"award-info":[{"award-number":["2022LNJJ10"]}],"id":[{"id":"10.13039\/501100011790","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chen Xiao-Ping Foundation"},{"name":"Development of Science and Technology of Hubei Province","award":["CXPJJH121005-01"],"award-info":[{"award-number":["CXPJJH121005-01"]}]},{"name":"Advanced Lung Cancer Targeted Therapy Research Foundation of China","award":["CTONG-YC20210303"],"award-info":[{"award-number":["CTONG-YC20210303"]}]},{"name":"National Multidisciplinary Cooperative Diagnosis and Treatment Capacity","award":["z027002"],"award-info":[{"award-number":["z027002"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Programmed death 1 (PD-1)\/programmed death 1 ligand 1 (PD-L1)-directed immunotherapy has revolutionized the treatments for advanced non-small cell lung cancer (NSCLC), whereas the optimal therapeutic combinations remain uncertain.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Our study encompassed phase II\/III randomized controlled trials (RCTs) that involved anti-PD-(L)1-based therapies for stage-IV NSCLC. The primary outcomes included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and incidences of adverse events. Subgroup analyses were conducted by treatment lines, PD-L1 expression levels, histological types, and metastatic sites.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Our analysis incorporated 38 publications, covering 14 therapeutic combinations and involving 18\u200a048 participants. PD-(L)1+chemotherapy (CT), PD-(L)1+ cytotoxic T lymphocyte-associated antigen-4 (CTLA4) +CT, and PD-(L)1+ T-cell immunoglobulin and ITIM domain were notably effective in prolonging OS. Overall, PD-(L)1+CT and PD-(L)1+CT+ vascular endothelial growth factor (VEGF) were significantly beneficial for PFS and ORR. As for the subsequent-line treatments, incorporating radiotherapy can enhance PFS and ORR (ranked fourth among enrolled treatments). For patients with PD-L1 &amp;lt;1%, PD-(L)1+CT+VEGF and PD-(L)1+CTLA4+CT were favorable approaches. Conversely, in patients with PD-L1 \u226550%, PD-(L)1+CT represented an effective treatment. Patients with nonsquamous cell carcinoma or liver metastases might benefit from the addition of VEGF. In cases of squamous cell carcinoma or brain metastases, the combination of PD-(L)1+CTLA4+CT yielded superior benefits.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study underscores the enhanced efficacy of combination immunotherapies over monotherapy. It highlights the necessity for personalized treatment, considering individual factors. These insights are vital for clinical decision making in the management of advanced NSCLC.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jnci\/djae137","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T07:54:59Z","timestamp":1718265299000},"page":"1571-1586","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and safety of personalized optimal PD-(L)1 combinations in advanced NSCLC: a network meta-analysis"],"prefix":"10.1093","volume":"116","author":[{"given":"Xianjing","family":"Chu","sequence":"first","affiliation":[{"name":"Department of Oncology, Xiangya Hospital, Central South University , Changsha,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentao","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Oncology, Xiangya Hospital, Central South University , Changsha,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaoyang","family":"Ning","sequence":"additional","affiliation":[{"name":"Department of Oncology, Xiangya Hospital, Central South University , Changsha,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4483-0615","authenticated-orcid":false,"given":"Rongrong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Oncology, Xiangya Hospital, Central South University , Changsha,","place":["China"]},{"name":"Xiangya Lung Cancer Center, Xiangya Hospital, Central South University , Changsha,","place":["China"]},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University , Changsha,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,17]]},"reference":[{"issue":"1","key":"2024100903340619300_djae137-B1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"2024100903340619300_djae137-B2","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","article-title":"Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment","volume":"94","author":"Duma","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"2024100903340619300_djae137-B3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/his.15080","article-title":"Molecular pathology of non-small cell carcinoma","volume":"84","author":"Yatabe","year":"2024","journal-title":"Histopathology"},{"key":"2024100903340619300_djae137-B4","doi-asserted-by":"crossref","first-page":"875488","DOI":"10.3389\/fimmu.2022.875488","article-title":"The long-term and short-term efficacy of immunotherapy in non-small cell lung cancer patients with brain metastases: a systematic review and meta-analysis","volume":"13","author":"Chu","year":"2022","journal-title":"Front Immunol"},{"issue":"8","key":"2024100903340619300_djae137-B5","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jama.2019.11058","article-title":"Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review","volume":"322","author":"Arbour","year":"2019","journal-title":"JAMA"},{"issue":"4","key":"2024100903340619300_djae137-B6","doi-asserted-by":"crossref","first-page":"340","DOI":"10.6004\/jnccn.2023.0020","article-title":"NCCN Guidelines(R) insights: non-small cell lung cancer, version 2.2023","volume":"21","author":"Ettinger","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"2024100903340619300_djae137-B7","doi-asserted-by":"crossref","first-page":"107441","DOI":"10.1016\/j.lungcan.2023.107441","article-title":"Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: results of an international expert panel meeting by the Italian association of thoracic oncology (AIOT)","volume":"187","author":"Gridelli","year":"2024","journal-title":"Lung Cancer"},{"key":"2024100903340619300_djae137-B8","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2024100903340619300_djae137-B9","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"7414","key":"2024100903340619300_djae137-B10","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"6","key":"2024100903340619300_djae137-B11","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamaoncol.2020.0409","article-title":"Efficacy and safety of pembrolizumab plus docetaxel vs docetaxel alone in patients with previously treated advanced non-small cell lung cancer: the PROLUNG phase 2 randomized clinical trial","volume":"6","author":"Arrieta","year":"2020","journal-title":"JAMA Oncol"},{"issue":"21","key":"2024100903340619300_djae137-B12","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1200\/JCO.20.03579","article-title":"Pembrolizumab plus ipilimumab or placebo for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u226550%: randomized, double-blind phase III KEYNOTE-598 study","volume":"39","author":"Boyer","year":"2021","journal-title":"J Clin Oncol"},{"key":"2024100903340619300_djae137-B13","doi-asserted-by":"crossref","first-page":"100164","DOI":"10.1016\/j.iotech.2022.100164","article-title":"59MO final analysis of AK105-302: a randomized, double-blind, placebo-controlled, phase III trial of penpulimab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC","volume":"16","author":"Han","year":"2022","journal-title":"Immuno-Oncol Technol"},{"issue":"11","key":"2024100903340619300_djae137-B14","doi-asserted-by":"crossref","first-page":"S1975","DOI":"10.1016\/j.jtho.2017.09.867","article-title":"Poseidon: a phase 3 study of first-line durvalumab \u00b1 tremelimumab + chemotherapy vs chemotherapy alone in metastatic NSCLC","volume":"12","author":"Mok","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"4","key":"2024100903340619300_djae137-B15","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jtho.2020.11.025","article-title":"Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 trial","volume":"16","author":"Nishio","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"21","key":"2024100903340619300_djae137-B16","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1200\/JCO.22.00912","article-title":"Phase II randomized study of ramucirumab and pembrolizumab versus standard of care in advanced non-small-cell lung cancer previously treated with immunotherapy-lung-MAP S1800A","volume":"40","author":"Reckamp","year":"2022","journal-title":"J Clin Oncol"},{"key":"2024100903340619300_djae137-B17","first-page":"S1680","article-title":"540P Phase III study of serplulimab plus chemotherapy as first-line therapy for advanced squamous non-small cell lung cancer: ASTRUM-004 Asian subgroup","volume":"34","author":"Zhou","year":"2023","journal-title":"Ann Oncol"},{"issue":"9","key":"2024100903340619300_djae137-B18","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.jtho.2021.04.011","article-title":"Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: results from a randomized, double-blind, phase 3 trial (ORIENT-12)","volume":"16","author":"Zhou","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2024100903340619300_djae137-B19","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.lungcan.2022.07.013","article-title":"Final overall survival data of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC in the phase 3 ORIENT-11 study","volume":"171","author":"Zhang","year":"2022","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"4","key":"2024100903340619300_djae137-B20","doi-asserted-by":"crossref","first-page":"S760","DOI":"10.1016\/S1556-0864(21)01957-2","article-title":"Survival data from EMPOWER-Lung 4: phase II study of cemiplimab plus ipilimumab in the second-line (2L) treatment of advanced non-small cell lung cancer (NSCLC)","volume":"16","author":"Shim","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"1","key":"2024100903340619300_djae137-B21","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jtho.2018.08.004","article-title":"24-month overall survival from KEYNOTE-021 Cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous non-small cell lung cancer","volume":"14","author":"Borghaei","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"3","key":"2024100903340619300_djae137-B22","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1200\/JCO.22.00727","article-title":"Toripalimab plus chemotherapy for patients with treatment-naive advanced non-small-cell lung cancer: a multicenter randomized phase III trial (CHOICE-01)","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"2024100903340619300_djae137-B23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.lungcan.2023.01.013","article-title":"NEPTUNE China cohort: first-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer","volume":"178","author":"Cheng","year":"2023","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"5","key":"2024100903340619300_djae137-B24","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jamaoncol.2021.0366","article-title":"Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer a phase 3 randomized clinical trial","volume":"7","author":"Wang","year":"2021","journal-title":"JAMA Oncol"},{"issue":"11","key":"2024100903340619300_djae137-B25","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","article-title":"IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC","volume":"16","author":"Socinski","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2024100903340619300_djae137-B26","doi-asserted-by":"crossref","first-page":"S816","DOI":"10.1016\/j.annonc.2020.08.1577","article-title":"Tislelizumab + chemotherapy vs chemotherapy alone as first-line treatment for locally advanced\/metastatic nonsquamous NSCLC","volume":"31","author":"Lu","year":"2020","journal-title":"Ann Oncol"},{"issue":"14","key":"2024100903340619300_djae137-B27","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"2024100903340619300_djae137-B28","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jtho.2022.12.017","article-title":"Camrelizumab plus carboplatin and pemetrexed as first-line treatment for advanced nonsquamous NSCLC: extended follow-up of CameL phase 3 trial","volume":"18","author":"Zhou","year":"2023","journal-title":"J Thorac Oncol."},{"issue":"7","key":"2024100903340619300_djae137-B29","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"issue":"7","key":"2024100903340619300_djae137-B30","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S2213-2600(23)00135-2","article-title":"Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"11","author":"Lu","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"6","key":"2024100903340619300_djae137-B31","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1200\/JCO.22.01503","article-title":"Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in CheckMate 227","volume":"41","author":"Brahmer","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"2024100903340619300_djae137-B32","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1470-2045(21)00658-6","article-title":"Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial","volume":"23","author":"Schoenfeld","year":"2022","journal-title":"Lancet Oncol"},{"issue":"21","key":"2024100903340619300_djae137-B33","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"New Engl J Med"},{"issue":"8","key":"2024100903340619300_djae137-B34","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.jtho.2020.03.028","article-title":"Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial","volume":"15","author":"Jotte","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"2","key":"2024100903340619300_djae137-B35","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"2024100903340619300_djae137-B36","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1001\/jamaoncol.2021.2209","article-title":"Nivolumab plus ipilimumab vs nivolumab for previously treated patients with stage IV squamous cell lung cancer: the lung-MAP S1400I phase 3 randomized clinical trial","volume":"7","author":"Gettinger","year":"2021","journal-title":"JAMA Oncol"},{"issue":"6","key":"2024100903340619300_djae137-B37","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","article-title":"Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study","volume":"23","author":"Cho","year":"2022","journal-title":"Lancet Oncol"},{"issue":"20","key":"2024100903340619300_djae137-B38","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.1158\/1078-0432.CCR-22-1687","article-title":"A randomized comparison of nivolumab versus nivolumab + docetaxel for previously treated advanced or recurrent ICI-na\u00efve non-small cell lung cancer: TORG1630","volume":"28","author":"Taniguchi","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2024100903340619300_djae137-B39","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jtho.2021.10.023","article-title":"CCTG BR34: a randomized phase 2 trial of durvalumab and tremelimumab with or without platinum-based chemotherapy in patients with metastatic NSCLC","volume":"17","author":"Leighl","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"9","key":"2024100903340619300_djae137-B40","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.annonc.2021.06.004","article-title":"Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer","volume":"32","author":"Sugawara","year":"2021","journal-title":"Ann Oncol"},{"issue":"4","key":"2024100903340619300_djae137-B41","first-page":"107422","article-title":"Patient-reported outcomes with durvalumab with or without tremelimumab versus standard chemotherapy as first-line treatment of metastatic non-small-cell lung cancer (MYSTIC)","volume":"186","author":"Garon","year":"2021","journal-title":"Lung Cancer"},{"issue":"5","key":"2024100903340619300_djae137-B42","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.annonc.2020.02.006","article-title":"ARCTIC: Durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer","volume":"31","author":"Planchard","year":"2020","journal-title":"Ann Oncol"},{"issue":"2","key":"2024100903340619300_djae137-B43","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S1470-2045(21)00650-1","article-title":"Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial","volume":"23","author":"Zhou","year":"2022","journal-title":"Lancet Oncol"},{"issue":"7","key":"2024100903340619300_djae137-B44","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1038\/s41591-023-02385-6","article-title":"Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495\/KeyImPaCT trial interim results","volume":"29","author":"Gutierrez","year":"2023","journal-title":"Nat Med"},{"issue":"4","key":"2024100903340619300_djae137-B45","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jtho.2021.11.018","article-title":"Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-Sq): a phase 3 trial","volume":"17","author":"Ren","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"2","key":"2024100903340619300_djae137-B46","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jtho.2020.10.001","article-title":"Randomized phase 2 studies of checkpoint inhibitors alone or in combination with pegilodecakin in patients with metastatic NSCLC (CYPRESS 1 and CYPRESS 2)","volume":"16","author":"Spigel","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2024100903340619300_djae137-B47","doi-asserted-by":"crossref","first-page":"S1429","DOI":"10.1016\/j.annonc.2021.10.139","article-title":"120O Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS \u22651% (LEAP-007): a phase III, randomized, double-blind study","volume":"32","author":"Yang","year":"2021","journal-title":"Ann Oncol"},{"issue":"11","key":"2024100903340619300_djae137-B48","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1038\/s41591-022-01977-y","article-title":"Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial","volume":"28","author":"Gogishvili","year":"2022","journal-title":"Nat Med"},{"issue":"3","key":"2024100903340619300_djae137-B49","first-page":"774","article-title":"Distribution of PD-L1 expression and its relationship with clinicopathological variables: an audit from 1071 cases of surgically resected non-small cell lung cancer","volume":"12","author":"Chen","year":"2019","journal-title":"Int J Clin Exp Pathol"},{"key":"2024100903340619300_djae137-B50","doi-asserted-by":"crossref","first-page":"956788","DOI":"10.3389\/fphar.2022.956788","article-title":"The influence of baseline characteristics on the efficacy of immune checkpoint inhibitors for advanced lung cancer: a systematic review and meta-analysis","volume":"13","author":"Xiao","year":"2022","journal-title":"Front Pharmacol"},{"issue":"1","key":"2024100903340619300_djae137-B51","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-021-01164-5","article-title":"Combination strategies to maximize the benefits of cancer immunotherapy","volume":"14","author":"Zhu","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2024100903340619300_djae137-B52","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000337","article-title":"Consensus guidelines for the definition, detection and interpretation of immunogenic cell death","volume":"8","author":"Galluzzi","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"6","key":"2024100903340619300_djae137-B53","doi-asserted-by":"crossref","first-page":"e1438107","DOI":"10.1080\/2162402X.2018.1438107","article-title":"Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells","volume":"7","author":"Gravett","year":"2018","journal-title":"Oncoimmunology"},{"issue":"3","key":"2024100903340619300_djae137-B54","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.immuni.2018.03.007","article-title":"Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies","volume":"48","author":"Patel","year":"2018","journal-title":"Immunity"},{"issue":"3-4","key":"2024100903340619300_djae137-B55","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1023\/B:CANC.0000031769.14728.bc","article-title":"Metabolic oxidation\/reduction reactions and cellular responses to ionizing radiation: a unifying concept in stress response biology","volume":"23","author":"Spitz","year":"2004","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"2024100903340619300_djae137-B56","doi-asserted-by":"crossref","first-page":"e32542","DOI":"10.1371\/journal.pone.0032542","article-title":"Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells","volume":"7","author":"Wan","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"2024100903340619300_djae137-B57","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J Exp Med"},{"issue":"1","key":"2024100903340619300_djae137-B58","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/ijc.28015","article-title":"Radiation-induced loss of cell surface CD47 enhances immune-mediated clearance of human papillomavirus-positive cancer","volume":"133","author":"Vermeer","year":"2013","journal-title":"Int J Cancer"},{"issue":"3","key":"2024100903340619300_djae137-B59","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.4049\/jimmunol.160.3.1224","article-title":"Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells","volume":"160","author":"Oyama","year":"1998","journal-title":"J Immunol"},{"issue":"9","key":"2024100903340619300_djae137-B60","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.tips.2019.07.001","article-title":"Tumor vasculatures: a new target for cancer immunotherapy","volume":"40","author":"Liu","year":"2019","journal-title":"Trends Pharmacol Sci"},{"issue":"2","key":"2024100903340619300_djae137-B61","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1365-2567.2010.03357.x","article-title":"Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages","volume":"132","author":"Buhtoiarov","year":"2011","journal-title":"Immunology"},{"issue":"12","key":"2024100903340619300_djae137-B62","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1002\/eji.201444879","article-title":"Human regulatory T cells lack the cyclophosphamide-extruding transporter ABCB1 and are more susceptible to cyclophosphamide-induced apoptosis","volume":"44","author":"Dimeloe","year":"2014","journal-title":"Eur J Immunol"},{"issue":"535","key":"2024100903340619300_djae137-B63","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz8235","article-title":"Strong vaccine responses during chemotherapy are associated with prolonged cancer survival","volume":"12","author":"Melief","year":"2020","journal-title":"Sci Transl Med"},{"issue":"1","key":"2024100903340619300_djae137-B64","doi-asserted-by":"crossref","first-page":"464","DOI":"10.4049\/jimmunol.172.1.464","article-title":"Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer","volume":"172","author":"Nefedova","year":"2004","journal-title":"J Immunol"},{"key":"2024100903340619300_djae137-B65","doi-asserted-by":"crossref","first-page":"12113","DOI":"10.2147\/OTT.S276150","article-title":"Anti-angiogenic therapy in the treatment of non-small cell lung cancer","volume":"13","author":"Tian","year":"2020","journal-title":"Onco Targets Ther"},{"issue":"8","key":"2024100903340619300_djae137-B66","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.4049\/jimmunol.1303116","article-title":"CD47 signaling regulates the immunosuppressive activity of VEGF in T cells","volume":"193","author":"Kaur","year":"2014","journal-title":"J Immunol"},{"issue":"6","key":"2024100903340619300_djae137-B67","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1158\/2159-8290.CD-20-1209","article-title":"Development of immunotherapy combination strategies in cancer","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov"},{"issue":"1","key":"2024100903340619300_djae137-B68","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12943-023-01800-3","article-title":"Co-inhibition of TIGIT and PD-1\/PD-L1 in cancer immunotherapy: mechanisms and clinical trials","volume":"22","author":"Chu","year":"2023","journal-title":"Mol Cancer"},{"issue":"9","key":"2024100903340619300_djae137-B69","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/S1470-2045(21)00333-8","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis","volume":"22","author":"Zhou","year":"2021","journal-title":"Lancet Oncol"},{"key":"2024100903340619300_djae137-B70","doi-asserted-by":"crossref","first-page":"840313","DOI":"10.3389\/fimmu.2022.840313","article-title":"Interleukin-10 is a promising marker for immune-related adverse events in patients with non-small cell lung cancer receiving immunotherapy","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"2024100903340619300_djae137-B71","doi-asserted-by":"crossref","first-page":"1146905","DOI":"10.3389\/fonc.2023.1146905","article-title":"Checkpoint inhibitors as dual immunotherapy in advanced non-small cell lung cancer: a meta-analysis","volume":"13","author":"Alifu","year":"2023","journal-title":"Front Oncol"},{"issue":"10422","key":"2024100903340619300_djae137-B72","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","article-title":"Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study","volume":"403","author":"Tsai","year":"2023","journal-title":"Lancet"},{"issue":"9","key":"2024100903340619300_djae137-B73","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.21037\/tlcr-22-644","article-title":"International consensus on radiotherapy in metastatic non-small cell lung cancer","volume":"11","author":"Zhu","year":"2022","journal-title":"Transl Lung Cancer Res"},{"issue":"4","key":"2024100903340619300_djae137-B74","doi-asserted-by":"crossref","first-page":"237","DOI":"10.5306\/wjco.v13.i4.237","article-title":"GOECP\/SEOR radiotherapy guidelines for non-small-cell lung cancer","volume":"13","author":"Rodriguez De Dios","year":"2022","journal-title":"World J Clin Oncol"},{"issue":"10055","key":"2024100903340619300_djae137-B75","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/S0140-6736(16)30825-X","article-title":"Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial","volume":"388","author":"Mulvenna","year":"2016","journal-title":"Lancet"},{"issue":"10","key":"2024100903340619300_djae137-B76","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1200\/JCO.19.02767","article-title":"Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: phase III trial NRG oncology CC001","volume":"38","author":"Brown","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"2024100903340619300_djae137-B77","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1470-2045(17)30441-2","article-title":"Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC.3): a multicentre, randomised, controlled, phase 3 trial","volume":"18","author":"Brown","year":"2017","journal-title":"Lancet Oncol"},{"key":"2024100903340619300_djae137-B78","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35310","article-title":"Dose-intensified stereotactic body radiotherapy for painful vertebral metastases: a randomized phase 3 trial","author":"Guckenberger","year":"2024","journal-title":"Cancer"},{"issue":"1","key":"2024100903340619300_djae137-B79","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/CJI.0000000000000443","article-title":"The association of immunotherapy with the overall survival of inoperable stage III non-small cell lung cancer patients who do not receive chemoradiation","volume":"46","author":"Amin","year":"2023","journal-title":"J Immunother"},{"issue":"5","key":"2024100903340619300_djae137-B80","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2012.43.7954","article-title":"Palliative radiation therapy practice in patients with metastatic non-small-cell lung cancer: a Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) study","volume":"31","author":"Chen","year":"2013","journal-title":"J Clin Oncol"},{"key":"2024100903340619300_djae137-B81","first-page":"A685","article-title":"602 A phase I trial of atezolizumab and varlilumab in combination with radiation in patients with metastatic non-small cell lung cancer (NSCLC)","volume":"11(suppl 1)","author":"Malhotra","year":"2023","journal-title":"J ImmunoTher Cancer"},{"key":"2024100903340619300_djae137-B82","doi-asserted-by":"crossref","first-page":"8513","DOI":"10.1200\/JCO.2022.40.16_suppl.8513","article-title":"Safety results of NRG-LU004: phase I trial of accelerated or conventionally fractionated radiotherapy combined with durvalumab in PD-L1\u2013high locally advanced non-small cell lung cancer","volume":"40(suppl 16)","author":"Lin","year":"2022","journal-title":"J Clin Oncol"},{"key":"2024100903340619300_djae137-B83","author":"Khan"},{"key":"2024100903340619300_djae137-B84","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3389\/fonc.2012.00191","article-title":"Radiation-induced effects and the immune system in cancer","volume":"2","author":"Kaur","year":"2012","journal-title":"Front Oncol"},{"key":"2024100903340619300_djae137-B85","doi-asserted-by":"crossref","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"issue":"12","key":"2024100903340619300_djae137-B86","doi-asserted-by":"crossref","first-page":"7516","DOI":"10.4049\/jimmunol.174.12.7516","article-title":"Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor","volume":"174","author":"Lugade","year":"2005","journal-title":"J Immunol"},{"issue":"4","key":"2024100903340619300_djae137-B87","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.ijrobp.2011.09.049","article-title":"Maximizing tumor immunity with fractionated radiation","volume":"83","author":"Schaue","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16","key":"2024100903340619300_djae137-B88","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1158\/1078-0432.CCR-14-2824","article-title":"Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions","volume":"21","author":"Filatenkov","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"17","key":"2024100903340619300_djae137-B89","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2024100903340619300_djae137-B90","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s40425-019-0634-9","article-title":"Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination","volume":"7","author":"Grapin","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"305","key":"2024100903340619300_djae137-B91","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1259\/0007-1285-26-305-234","article-title":"Whole body irradiation; radiobiology or medicine?","volume":"26","author":"Mole","year":"1953","journal-title":"Br J Radiol"},{"issue":"8","key":"2024100903340619300_djae137-B92","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.it.2018.06.001","article-title":"Immunological mechanisms responsible for radiation-induced abscopal effect","volume":"39","author":"Rodriguez-Ruiz","year":"2018","journal-title":"Trends Immunol"},{"key":"2024100903340619300_djae137-B93","doi-asserted-by":"crossref","first-page":"106663","DOI":"10.1016\/j.intimp.2020.106663","article-title":"Abscopal effect in radioimmunotherapy","volume":"85","author":"Ashrafizadeh","year":"2020","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"2024100903340619300_djae137-B94","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/s41591-018-0232-2","article-title":"Radiotherapy induces responses of lung cancer to CTLA-4 blockade","volume":"24","author":"Formenti","year":"2018","journal-title":"Nat Med"},{"issue":"7","key":"2024100903340619300_djae137-B95","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/nrc3958","article-title":"The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence","volume":"15","author":"Barker","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2024100903340619300_djae137-B96","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000492","article-title":"Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials","volume":"8","author":"Chen","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"2","key":"2024100903340619300_djae137-B97","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/j.ijrobp.2023.06.774","article-title":"SABRSeq: A randomized phase Ib trial of SABR sequencing with pembrolizumab in metastatic non-small cell lung cancer (NSCLC)","volume":"117","author":"Siva","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"2024100903340619300_djae137-B98","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ccr.2013.09.014","article-title":"Low-dose irradiation programs macrophage differentiation to an iNOS(+)\/M1 phenotype that orchestrates effective T cell immunotherapy","volume":"24","author":"Klug","year":"2013","journal-title":"Cancer Cell"},{"issue":"11","key":"2024100903340619300_djae137-B99","doi-asserted-by":"crossref","first-page":"e1046028","DOI":"10.1080\/2162402X.2015.1046028","article-title":"A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab","volume":"4","author":"Chandra","year":"2015","journal-title":"Oncoimmunology"},{"issue":"3","key":"2024100903340619300_djae137-B100","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1667\/RR2773.1","article-title":"Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS)","volume":"177","author":"Park","year":"2012","journal-title":"Radiat Res"},{"issue":"1","key":"2024100903340619300_djae137-B101","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s12967-023-04089-4","article-title":"Optimal timing and sequence of combining stereotactic radiosurgery with immune checkpoint inhibitors in treating brain metastases: clinical evidence and mechanistic basis","volume":"21","author":"Tian","year":"2023","journal-title":"J Transl Med"},{"issue":"1","key":"2024100903340619300_djae137-B102","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-018-0647-8","article-title":"Abscopal effect of radiotherapy combined with immune checkpoint inhibitors","volume":"11","author":"Liu","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"11","key":"2024100903340619300_djae137-B103","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.jtho.2023.09.078","article-title":"OA14.05 5-year survival of pembrolizumab plus chemotherapy for metastatic NSCLC with PD-L1 tumor proportion score &lt;1%","volume":"18","author":"Gadgeel","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"16","key":"2024100903340619300_djae137-B104","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1158\/1078-0432.CCR-20-0175","article-title":"Biomarkers associated with beneficial PD-1 checkpoint blockade in non-small cell lung cancer (NSCLC) identified using high-plex digital spatial profiling","volume":"26","author":"Zugazagoitia","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2024100903340619300_djae137-B105","doi-asserted-by":"crossref","first-page":"9043","DOI":"10.1200\/JCO.2022.40.16_suppl.9043","article-title":"Three-year outcomes and correlative analyses in patients with non-small cell lung cancer (NSCLC) and a very high PD-L1 tumor proportion score (TPS) \u226590% treated with first-line pembrolizumab","volume":"40(suppl 16)","author":"Ricciuti","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"2024100903340619300_djae137-B106","doi-asserted-by":"crossref","first-page":"107634","DOI":"10.1016\/j.isci.2023.107634","article-title":"Radiomics and deep learning models to differentiate lung adenosquamous carcinoma: a multicenter trial","volume":"26","author":"Chu","year":"2023","journal-title":"iScience"},{"issue":"5","key":"2024100903340619300_djae137-B107","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1158\/2326-6066.CIR-16-0325","article-title":"Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC","volume":"5","author":"Tumeh","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"2024100903340619300_djae137-B108","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.semcancer.2017.12.002","article-title":"Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics","volume":"52(Pt 2)","author":"Hegde","year":"2018","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"2024100903340619300_djae137-B109","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"issue":"8","key":"2024100903340619300_djae137-B110","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"2024100903340619300_djae137-B111","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2217\/imt-2022-0051","article-title":"Immunotherapy plus stereotactic body radiation therapy or whole-brain radiation therapy in brain metastases","volume":"15","author":"Amin","year":"2023","journal-title":"Immunotherapy"},{"issue":"3","key":"2024100903340619300_djae137-B112","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006243","article-title":"Heterogeneity of tumor immune microenvironment of EGFR\/ALK-positive tumors versus EGFR\/ALK-negative tumors in resected brain metastases from lung adenocarcinoma","volume":"11","author":"Xiao","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"7","key":"2024100903340619300_djae137-B113","doi-asserted-by":"crossref","first-page":"832","DOI":"10.6004\/jnccn.2020.7547","article-title":"Impact of immunotherapy on the survival of patients with cancer and brain metastases","volume":"18","author":"Amin","year":"2020","journal-title":"J Natl Compreh Cancer Netw"},{"key":"2024100903340619300_djae137-B114","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.lungcan.2022.03.006","article-title":"Bone metastasis attenuates efficacy of immune checkpoint inhibitors and displays \u201ccold\u201d immune characteristics in non-small cell lung cancer","volume":"166","author":"Zhu","year":"2022","journal-title":"Lung Cancer"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djae137\/58498852\/djae137.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/116\/10\/1571\/59634354\/djae137.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/116\/10\/1571\/59634354\/djae137.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T03:35:11Z","timestamp":1728444911000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/116\/10\/1571\/7695242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,17]]},"references-count":114,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,6,17]]},"published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djae137","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,6,17]]}}}